KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets: 2018-2024

Historic Assets for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $531.2 million.

  • Castle Biosciences' Assets rose 9.37% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.8 million, marking a year-over-year increase of 9.37%. This contributed to the annual value of $531.2 million for FY2024, which is 17.18% up from last year.
  • Latest data reveals that Castle Biosciences reported Assets of $531.2 million as of FY2024, which was up 17.18% from $453.3 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Assets peaked at $531.2 million during FY2024, and registered a low of $439.3 million during FY2020.
  • Its 3-year average for Assets is $477.3 million, with a median of $453.3 million in 2023.
  • In the last 5 years, Castle Biosciences' Assets spiked by 266.88% in 2020 and then decreased by 3.30% in 2022.
  • Yearly analysis of 5 years shows Castle Biosciences' Assets stood at $439.3 million in 2020, then climbed by 5.29% to $462.6 million in 2021, then dropped by 3.30% to $447.3 million in 2022, then climbed by 1.34% to $453.3 million in 2023, then rose by 17.18% to $531.2 million in 2024.